肝静脉压力梯度在肝硬化门静脉高压症患者中的临床应用

曹旬旬; 陆伦根

doi:10.3969/j.issn.1001-5256.2013.09.022

肝静脉压力梯度在肝硬化门静脉高压症患者中的临床应用

DOI: 10.3969/j.issn.1001-5256.2013.09.022

上海交通大学附属第一人民医院消化内科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 3372
- HTML全文浏览量: 11
- PDF下载量: 670
- 被引次数: 0
出版历程
- 收稿日期: 2012-12-10
- 出版日期: 2013-09-20

Clinical utility of hepatic venous pressure gradient for predicting outcome and guiding treatment of cirrhosis and portal hypertension

Department of Gastroenterology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine

摘要

摘要: 测量肝静脉压力梯度(HVPG)是评估门静脉高压症最常用的方法。大量研究表明,HVPG可作为食管静脉曲张出血的预测因子,此外,HVPG还可作为一个预后指标,可方便临床医生以其做参考为静脉曲张出血的一级预防和二级预防来制定合适的治疗策略。现阶段的治疗目标是使HVPG下降到12 mm Hg以下或比基线值下降20%,达到此目标的患者其食管静脉曲张的首次出血和再出血的风险均大大降低。对于一级预防,非选择性的β受体阻滞剂,如心得安,临床已广泛应用;然而,再出血的发生率仍然很高,临床上常用包括非选择性β受体阻滞剂在内的药物联合治疗和内镜干预,如经颈静脉肝内门体静脉分流术(TIPS)、内镜下硬化剂注射和内镜下套扎。主要探讨目前HVPG的测量方法及其临床应用,并重点对在肝硬化中HVPG对食管静脉曲张出血和再出血及治疗反应的预测作用做详细阐述。
- 肝静脉压力梯度 /
- 肝硬化 /
- 高血压,门静脉 /
- 食管和胃静脉曲张
Abstract: Measurement of the hepatic venous pressure gradient ( HVPG) remains the most commonly used method to assess portal hypertension ( clinically defined as above the normal range of 1- 5 mm Hg) . HVPG measurement can also serve as a predictor of variceal bleeding ( increased risk associated with >10-12 mm Hg) and as a prognostic indicator by which treating physicians may design appropriate therapeutic strategies for primary and secondary prophylaxis. The current treatments aim to reduce the HVPG to < 12 mm Hg or achieve a 20%reduction from baseline, both of which are associated with significantly lower risk of variceal bleeding and rebleeding. For primary prevention, non- selective beta- blockers, such as propranolol, are currently used; however, rebleeding incidence remains high and is frequently treated by a combination of drugs, including the non- selective beta- blockers, and endoscopic management, such as transjugular intrahepatic portosystemic shunting, endoscopic sclerotherapy, and endoscopic band ligation. We discuss the current HVPG measurement methods as well as the clinical applications, detailing its potential as a prognostic indicator of variceal bleeding and rebleeding in various liver conditions, such as cirrhosis, and in response to treatment.
- hepatic venous pressure gradient /
- liver cirrhosis /
- hypertension, portal /
- esophageal and gastric varices

HTML全文

参考文献(23)

[1]MYERS J, TAYLOR W.An estimation of portal venous pressure by occlusive catheterization of a hepatic venule[J].J Clin Invest, 1951, 30:662-663.

[2]ZUIN R, GATTA A, MERKEL C, et al.Evaluation of peritoneoscopic and oesophagoscopic findings as indexes of portal hypertension in patients with liver cirrhosis[J].Italian J Gastroenterol, 1982, 14:214-219.

[3]BARI K, GARCIA-TSAO G.Treatment of portal hypertension[J].World J Gastroenterol, 2012, 18 (11) :1166-1175.

[4]SUK KT, KIM CH, PARK SH, et al.Comparison of hepatic venous pressure gradient and two models of end-stage liver disease for predicting the survival in patient with decompensated liver cirrhosis[J].J Clin Gastroenterol, 2012, 46 (10) :880-886.

[5]RIPOLL C, GROSZMANN RJ, GARCIA-TSAO G, et al.Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis[J].J Hepatol, 2009, 50 (5) :923-928.

[6]RINCóN D, lo LACONO O, TEJEDOR M, et al.Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis[J].Scand J Gastroenterol, 2012, Aug 8.[Epub ahead of print].

[7]GROSZMANN RJ, BOSCH J, GRACE ND, et al.Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage[J].Gastroenterology, 1990, 99 (5) :1401-1407.

[8]MERKEL C, SACERDOTI D, BOLOGNESI M, et al.Doppler sonography and hepatic vein catheterization in portal hypertension:assessment of agreement in evaluating severity and response to treatment[J].J Hepatol, 1998, 28 (4) :622-630.

[9]GULZAR GM, ZARGAR SA, JALAL S.Correlation of hepatic venous pressure gradient with variceal bleeding, size of esophageal varices, etiology, ascites and degree of liver dysfunction in cirrhosis of liver[J].Indian J Gastroenterol, 2009, 28 (2) :59-61.

[10]VILLANUEVA C, ARACIL C, COLOMO A, et al.Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding[J].Gastroenterology, 2009, 137 (1) :119-128.

[11]de-MADARIA E, PALAZON JM, HERNANDEZ FT.Acute and chronic hemodynamic changes after propranolol in patients with cirrhosis under primary and secondary prophylaxis of variceal bleeding:a polot study[J].Eur J Gastroenterol Hepatol, 2010, 22 (5) :507-512.

[12]KIM MY, BAIK SK, SUK KT.Measurement of hepatic venous pressure gradient in liver cirrhosis:relationship with the status of cirrhosis, varices, and ascites in Koreal[J].Korean J Hepatol, 2008, 14 (2) :150-158.

[13]la MURA V, ABRALDES JG, RAFFA S, et al.Prognostic value of acute hemodynamic response to i.v.propranolol in patients with cirrhosis and portal hypertension[J].J Hepatol, 2009, 51 (2) :279-287.

[14]HOBOLTH L, BENDTSEN F, MOLLER S.Indications for portal pressure measurement in chronic liver disease[J].Scand J Gastroenterol, 2012, 8-9 (47) :887-892.

[15]THABUT D, BERNARD-CHABERT B.Management of acute bleeding from portal hypertension[J].Best Pract Res Clin Gastroenterol, 2007, 21 (1) :19-29.

[16]ABRALEDS JG, VILLANUEVA C, BANARES R.Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy[J].J Hepatol, 2008, 48 (2) :229-236.

[17]BAARES R, CATALINA MV, RIPOLL C, et al.Prognostic markers in patients who have recovered from an acute variceal bleeding:role of HVPG measurement[J].Disease Markers, 2011, 31 (3) :165-169.

[18]SHAO CP, XU XY.Progress in the prevention and treatment of bleeding gastroesophageal varices in patients with cirrhosis[J].J Clin Hepatol, 2012, 28 (9) :647-650. (in Chinese) 邵翠萍, 徐小元.肝硬化食管胃静脉曲张破裂出血的预防和治疗新进展[J].临床肝胆病杂志, 2012, 28 (9) :647-650.

[19]SHARMA P, KUMAR A, SHARMA BC, et al.Early identification of haemodynamic response to pharmacotherapy is essential for primary prophylaxis of variceal bleeding in patients with`high risk'varices[J].Aliment Pharmacol Ther, 2009, 30 (1) :48-60.

[20]VILLANUEVA C, ARACIL C, COLOMO A.Clinical trial:a randomized controlled study on prevention of varieal rebleeding comparing nadolol+ligation vs.hepatic venous pressure gradient-guided pharmacological therpy[J].Aliment Pharmacol Ther, 2009, 29 (4) :397-408.

[21]ADDLEY J, THAM TC, CASH WJ.Use of portal pressure studies in the management of variceal haemorrhage[J].World J Gastrointest Endosc, 2012, 4 (7) :281-289.

[22]D'AMICO G, GARCIA-PAGAN JC, LUCA A, et al.Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis:a systematic review[J].Gastroenterology, 2006, 131 (5) :1611-1624.

[23]AUGUSTIN S, GONZLEZ A, BADIA L, et al.Long-term follow-up of hemodynamic responders to pharmacological therapy after variceal bleeding[J].Hepatology, 2012, 56 (2) :706-714.

施引文献

资源附件(0)

访问统计